Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2009

View Archived Issues

Pimavanserin does not worsen parkinsonism in patients with PD and psychosis

NST-0021 prevents neurodegeneration in vivo in Alzheimer's model

Hydrogen sulphide-releasing latanoprost derivative shows potential for the treatment of glaucoma

Preliminary data show effects on sleep and memory with ramelteon in Parkinson's disease patients

BioSante updates status of LibiGel for FSD in menopausal women

Cytos reports disappointing results from phase IIa trial of hypertension vaccine CYT006-AngQb

Opexa reports preclinical data for autologous stem cell therapy for diabetes

Spectrum acquires former partner RIT Oncology and rights to Zevalin for NHL

Questcor submits sNDA to FDA for H.P. Acthar gel for infantile spasms

Alba Therapeutics to initiate next clinical trial for larazotide acetate

Cephalon reports positive results from phase II Nuvigil study

Novel dual MEK/ERK inhibitor shows antitumor activity

NicOx initiates proof-of-principle clinical study for NCX-6560

Sopherion completes enrollment in phase III Myocet breast cancer study

Quest forms alliance with IntelligentNano for nanotechnology-based SL-052

Nanobac and Eureka Genomics agree to terms for merger

Merck Serono and Fast Forward to accelerate development of MS treatments

Merck & Co. donates antimalarial candidate to Medicines for Malaria Venture

FDA approves Hologic's DNA tests for high-risk human papillomavirus

FDA accepts IND for Arno Therapeutics' Pan-DAC/Akt inhibitor, AR-42

Y's Therapeutics claims TNF-alpha release inhibitors for modulation of immune responses

Actelion Pharmaceuticals presents novel orexin receptor antagonists

Novel cathepsin C inhibitors described by GlaxoSmithKline

Novel carbostyryl derivatives described by Kyorin Pharmaceutical

Summit Corporation patents novel compounds with potential for Duchenne muscular dystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...